Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Oculis Holding AG Warrants (OCSAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/03/2025: OCSAW (3-star) is a REGULAR-BUY. BUY since 15 days. Simulated Profits (-13.94%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 50.77% | Avg. Invested days 21 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/03/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.85 - 11.50 | Updated Date 02/26/2025 |
52 Weeks Range 1.85 - 11.50 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Oculis Holding AG Warrants
Company Overview
History and Background
Oculis Holding AG is a biopharmaceutical company focused on developing and commercializing innovative treatments for ophthalmic diseases. While specific founding details of the warrant aspect are limited, warrants represent the right to purchase underlying shares at a specific price and time.
Core Business Areas
- Pharmaceutical Development: Research and development of novel ophthalmic therapies.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of new treatments.
- Commercialization: Bringing approved therapies to market.
- Warrant Issuance: Issuance of warrants providing investors with the option to purchase Oculis shares at a predetermined price.
Leadership and Structure
Details on Oculis's leadership team and organizational structure were not found. For specifics, consult Oculis Holding AG's investor relations page.
Top Products and Market Share
Key Offerings
- OCU400: A novel therapy targeting genetic mutations associated with retinal diseases. Details on market share and competitors are not publicly available. Potential competitors include companies focusing on gene therapies for inherited retinal diseases.
- OCU200: An anti-TNFu03b1 fusion protein for treating dry eye disease (DED). Details on market share and competitors are not publicly available. Competitors include companies with established DED treatments such as Allergan (Restasis, now AbbVie) and Novartis (Xiidra).
Market Dynamics
Industry Overview
The ophthalmology market is growing due to an aging population and increasing prevalence of eye diseases. Advancements in drug delivery, gene therapy, and personalized medicine are driving innovation.
Positioning
Oculis Holding AG aims to address unmet needs in the ophthalmology market with its pipeline of novel therapies. Its competitive advantage lies in its innovative drug development platform.
Total Addressable Market (TAM)
The global ophthalmology market is estimated to be worth billions of dollars. Oculis is positioned to capture a portion of this TAM by developing and commercializing successful therapies for various eye diseases. Specific TAM figures related to Oculis's targeted diseases were not found.
Upturn SWOT Analysis
Strengths
- Innovative drug development platform
- Pipeline of novel ophthalmic therapies
- Experienced management team
Weaknesses
- Dependence on successful clinical trial outcomes
- Limited commercialization experience (as a relatively young company)
- Financial resources for research and development are often a challenge for biotech
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of complementary technologies or assets
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ABBV
- NVS
Competitive Landscape
Oculis faces competition from established pharmaceutical companies with established ophthalmic products, but Oculis's novel approach offers an advantage.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data for Oculis Holding AG Warrants is limited due to its status as a warrant offering.
Future Projections: Future growth is dependent on the success of its clinical trials and the commercialization of its products. Analyst estimates are not readily available specifically for the warrants.
Recent Initiatives: Recent initiatives focus on advancing its clinical programs and securing partnerships.
Summary
Oculis Holding AG is a biopharmaceutical company with a promising pipeline of ophthalmic therapies. Its success depends on positive clinical trial results and effective commercialization. It faces competition from larger, more established companies, and managing financial resources is crucial for its long-term growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Press releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share figures are estimates and may vary. The warrant analysis is speculative and depends on factors such as the underlying stock performance and time to expiration.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oculis Holding AG Warrants
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-03 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website |
Full time employees 32 | Website | ||
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.